pembrolizumab + p53-SLP vaccine

This combination therapy consists of the immune checkpoint inhibitor pembrolizumab (Keytruda) and the p53-specific synthetic long peptide (p53-SLP) vaccine. Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to enhance T-cell mediated anti-tumor activity. The p53-SLP vaccine consists of 10 overlapping synthetic long peptides (averaging 30 amino acids in length) covering the core of the p53 protein from amino acids 70 to 251. It is formulated with the adjuvant Montanide ISA 51 to induce p53-specific T-cell responses. The combination is being investigated by the University Medical Center Groningen (UMCG) for the treatment of recurrent platinum-resistant ovarian cancer, aiming to overcome the immunosuppressive tumor microenvironment and boost the efficacy of vaccine-induced T-cells.

Brand names

Keytruda

Other names

pembrolizumab plus p53 synthetic long peptide vaccinep53-SLP vaccine + pembrolizumab